Tag Archives: TAVI

TCT 2022

TCT 2022 | PROTECTED TAVR

TCT 2022 | PROTECTED TAVR

Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of 16.7%. Even in the absence of symptoms, most patients (68-93%) have some type of diffusion imaging defect after TAVR implantation. The Sentinel cerebral protection device (CPD) (Boston Scientific) received FDA approval for the capture of emboligenic material that

The Best of Main Arena - SOLACI-SOCIME 2022

The Best of the SOLACI-SOCIME 2022 Main Arena: Structural—Selected Topics of TAVR

On the last session from day 1 of SOLACI-SOCIME 2022 on structural pathology, Dr. Raj Makkar, an international expert on the subject, talked about transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR), which presents several implantation challenges, such as insufficient anchoring, embolization, residual regurgitation, ring rupture, etc.  As opposed to patients with aortic

The Best of Main Arena - SOLACI-SOCIME 2022

The Best of the Main Arena at SOLACI-SOCIME 2022: TAVR Complex Anatomy

In the transcatheter aortic valve replacement (TAVR) session we had a presentation by Dr. John P. Vavalle (USA), head of the Structural Heart Disease Program at the University of North Carolina at Chapel Hill.  In his presentation, he showed how far the limits of percutaneous aortic valve implantation can be stretched by briefly showing successful

¿Cuál es el mejor tipo de dispositivo de cierre para el acceso del TAVI?

CHOICE-CLOSURE | Which Closure Device for TAVR is Better?

In patients who undergo transcatheter aortic valve replacement (TAVR) through transfemoral access, a closure device based on plug technology (MANTA VCD) is associated with a higher chance of access-related complications, but with shorter hemostasis time compared with a device with suture technology such as ProGlide VCD. Nowadays, most patients undergo TAVR through transfemoral access. Percutaneous

Miocardiopatía hipertrófica: análisis de una serie histórica

Is Troponin Elevation After TAVR Related to Mortality?

Troponins have long had diagnostic value not only for infarction. Their ability to predict mortality is well established for all cardiac conditions. Moreover, it has been demonstrated in all critically ill patients, including patients with COVID-19, regardless of the triggering condition. While their significance in COVID cases is backed by the literature, there was not

Webinar SOLACI-CACI-MicroPort

SOLACI-CACI 2021 Webinar | Challenges in TAVI – Severe CAD & Coronary Occlusion

Next Thursday, October 14, we will hold a joint event between SOLACI, CACI and the Microport company on “Challenges in TAVI: Severe Coronary Disease and Coronary Occlusion”. The activity is part of the satellite events of the SOLACI-CACI 2021 Congress and, as such, will have the participation of important international and Latin American speakers. Date:

SOLACI-CACI 2021 Virtual

SOLACI-CACI 2021 | Overcoming Challenges of the BALLOON EXPANDABLE TAVI Cases – EDWARDS Symposium

✔️ Watch again the Edwards Lifesciences Symposium in the SOLACI-CACI 2021 Virtual Congress.✔️ Topic: Overcoming Challenges of the BALLOON EXPANDABLE TAVI Cases.  👨‍🏫 Program: 00:05 – Opening – Dr. José Mangione (BRA). 02:20 – Aortic VinV in small annuli: Does the final gradient matter? – Dr. Adolfo Ferrero (ARG). 21:14 – Small Annuli and

Síndrome de Hiperperfusión cerebral post-angioplastia carotídea: una complicación prevenible

Silent Embolism during TAVR: Just Images or Potential Cognitive Deterioration?

Finding new cerebral ischemic imaging after transcatheter aortic valve replacement (TAVR) is almost the rule, especially for self-expandable valves. These images might disappear over the months but, unfortunately, they are associated to small but significative cognitive deterioration.  Most patients undergoing TAVR develop silent cerebral ischemic lesions (SCILs) that show in magnetic resonance imaging (MRI). The

infarto peri-procedimiento

Post TAVR Acute Coronary Syndrome: Frequency and Potential Damage

After Transcatheter Aortic Valve Replacement (TAVR) acute coronary syndromes (ACS) are rare and mostly present as non-ST elevation events. In this context, the few ST elevation events have bad prognosis, with close to 30% mortality at 30 days.  This study included patients undergoing TAVR between 2012 and 2017 admitted for acute coronary syndrome during followup. 

Top